A boosting skin vaccination with a biodegradable microneedle patch and protein constructed from sequences of influenza virus subtypes could improve the effectiveness of conventional influenza vaccines, according to a study led by Georgia State University.
Even if you’ve previously rejected vaccinating your children or have neglected to do so, physicians say it’s not too late to protect them against many preventable diseases.
Parents may be up to speed on what vaccines their children need for kindergarten, but may be less sure during high school years, a new national poll suggests.
A new study in mice shows that females vaccinated before pregnancy and infected with Zika virus while pregnant bear pups who show no trace of the virus. The findings offer the first evidence that an effective vaccine can protect vulnerable fetuses from Zika infection and resulting injury.
A lack of evidence that bats are key reservoirs of human disease has not prevented their vilification or efforts to exterminate bat colonies where threats are presumed to lurk. “The fact is that they provide important ecosystem services ... and we want them around,” says Tony Goldberg, a University of Wisconsin-Madison epidemiologist and virus hunter. “But bats are also increasingly acknowledged as hosts of medically significant viruses. I have mixed feelings about that.”
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
A national survey of parents, teens and healthcare providers revealed some major areas for improvement in preventive health communications to teens.
Researchers from Duke University School of Medicine and Tulane National Primate Research Center report findings in monkeys that demonstrates a CMV vaccine approach that appears to be capable of protecting the animal’s fetus from infection.
A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine. The findings support further development of the drug candidate for treating and preventing current coronavirus infections and potential future epidemic outbreaks.
A National Institutes of Health-funded study led by a team at the Georgia Institute of Technology and Emory University has shown that an influenza vaccine can produce robust immune responses and be administered safely with an experimental patch of dissolving microneedles.
A pair of scientists at The University of Texas at El Paso is one step closer to developing the first ever clinical Chagas disease vaccine. Researchers Rosa Maldonado, Ph.D., and Igor Almeida, Ph.D., both faculty in the Department of Biological Sciences, recently were granted a patent for “Mucin-Associated Surface Protein As Vaccine Against Chagas Disease.”
“Yarraman flu is a virus quickly infecting the US…” The mock announcement was enough to make readers worry. But when the name of the hypothetical illness was changed to “horse flu”, readers reported being less motivated to get a vaccine that would prevent them from contracting the illness. Based on a survey of 16,510 participants from 11 countries, the findings show that the way health information is communicated, matters. The multi-institutional investigation appeared in Emerging Infectious Diseases.
For decades, HIV has successfully evaded all efforts to create an effective vaccine but researchers at The Scripps Research Institute (TSRI) and the La Jolla Institute for Allergy and Immunology (LJI) are steadily inching closer. Their latest study, published in the current issue of Immunity, demonstrates that optimizing the mode and timing of vaccine delivery is crucial to inducing a protective immune response in a preclinical model.
This is the first licensed FMD diagnostic kit that can be manufactured on the U.S. mainland, critical for a rapid response in the event of a FMD outbreak.
Dimagi, Inc. and The Arnhold Institute for Global Health at the Icahn School of Medicine at Mount Sinai announced today that they are Grand Challenges Explorations winners, an initiative funded by the Bill & Melinda Gates Foundation.
Research done at Argonne National Laboratory’s Advanced Photon Source was vital to the process of identifying the structure, which provides a guide for designing a Lassa virus vaccine. Lassa virus is endemic to Africa and kills thousands of people a year; it is particularly deadly for pregnant women.
About a quarter of Americans suffer hardening of the valves by age 65 and about half by 85. Without a suitable drug, the only treatment is surgical replacement.
Cornell and Ludwig Institute for Cancer Research scientists have developed a way to produce a protein antigen that may be useful as vaccine for schistosomiasis – a parasitic disease that infects millions of people, mostly in tropical and subtropical climates – according to new research in the journal Protein Expression and Purification, June 2017.
Vaccines are scientifically proven to save lives and prevent major outbreaks of highly infectious diseases among large populations in a safe and effective way.
GW Researchers received a $3 million U01 grant from the National Institutes of Health to test the efficacy of a candidate recombinant hookworm vaccine, the next step in their goal to fight hookworm.
Building on insights from an HIV vaccine regimen in humans that had partial success during a phase 3 clinical trial in Thailand, a Duke-led research team used a more-is-better approach in monkeys that appeared to improve vaccine protection from an HIV-like virus.
UMB grants licensing rights for new vaccine candidate to Serenta Biotechnology, LLC, whose co-founder, Mark Shirtliff, PhD, professor at the University of Maryland School of Dentistry and the UM School of Medicine.
This is the first vaccine against an opioid to pass this stage of preclinical testing.
The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects. The findings will be presented by Dr. Seth Pollack, a physician-scientist at Fred Hutchinson Cancer Research Center, June 5 in a poster at the American Society of Clinical Oncology annual meeting in Chicago.
A team of scientists from The Scripps Research Institute (TSRI) has solved the structure of the viral machinery that Lassa virus uses to enter human cells. X-ray beams from the Stanford Synchrotron Radiation Lightsource (SSRL) at the Department of Energy's SLAC National Accelerator Laboratory gave the team the final piece in a puzzle they sought to solve for over 10 years.
This story starts with a young graduate student in San Diego and leads all the way to Sierra Leone, to a unique hospital where Lassa fever victims arrive by the thousands every year.
The vaccine for HPV is proving to have significant population-level effects in Connecticut, a new Yale School of Public Health study finds.
A novel vaccine therapy can generate immune responses in patients with head and neck squamous cell carcinoma (HNSCCa), according to researchers at the Abramson Cancer Center of the University of Pennsylvania. The treatment specifically targets human papillomavirus (HPV), which is frequently associated with HNSCCa, to trigger the immune response. Researchers will present the results of their pilot study during the 2017 American Society of Clinical Oncology Annual Meeting in Chicago (Abstract #6073).
A ‘designer’ manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, have shown to be successful in the development of a vaccine to counter Venezuelan Equine Encephalitis Virus (VEEV), a biothreat agent, and Chikungunya virus, a mosquito-borne illness causing severe outbreaks around the world, according to a study “Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alphavirus Vaccine Development,” published online May 22 in the journal, Vaccine, published by Elsevier.
Scientists could be one step closer to developing long-awaited vaccines against viruses such as Zika, West Nile or HIV, thanks to research at Penn State College of Medicine.
Scientists at The Scripps Research Institute (TSRI) have made another important advance in HIV vaccine design.
A new DNA vaccine when delivered to the skin prompts an immune response that produces antibodies to protect against toxic proteins associated with Alzheimer’s disease – without triggering severe brain swelling that earlier antibody treatments caused in some patients.
After analyzing the blood of a survivor of the 2013-16 Ebola outbreak, a team of scientists from academia, industry and the government has discovered the first natural human antibodies that can neutralize and protect animals against all three major disease-causing ebolaviruses. The findings, published online today in the journal Cell, could lead to the first broadly effective ebolavirus therapies and vaccines.
With a recent $1.8 million, five-year grant from the National Institutes of Health, Brandon DeKosky’s lab is using high-throughput techniques to analyze the behavior of B cells in the body.
Vaccinating pregnant mothers year-round against flu in the resource-challenged region of subtropical Nepal reduced infant flu virus infection rates by an average of 30 percent, increased birth weights by 15 percent and resulted in babies having less influenza, according to a study published in The Lancet Infectious Diseases. An international research team says expanding year-round flu vaccinations during pregnancy would also benefit children in other tropical and subtropical parts of the world.
Researchers have found a protein that stops cancer’s ability to prevent the immune system from destroying cancer cells. The protein, free C3d, has the potential to be developed into a cancer vaccine and a cancer treatment.
The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of Daniel W. Kulp, Ph.D., as associate professor in the Vaccine Center and the Translational Tumor Immunology Program.
Researchers from UT Southwestern Medical Center have developed a first-of-its-kind nanoparticle vaccine immunotherapy that targets several different cancer types.
Widely considered one of the greatest medical achievements of modern civilization, vaccines have prevented countless cases of disease and saved millions of lives.
Doctors and researchers in Southampton have developed a novel way of using a swab test which can rapidly diagnose flu and other viral infections in patients with severe respiratory conditions – resulting in shorter courses of antibiotics and less time in hospital.
/PRNewswire/ -- Protein Sciences Corporation is pleased to announce the publication of its manuscript entitled "Complete Study Demonstrating the Absence of Rhabdovirus in a Distinct Spodoptera frugiperda (Sf9) Cell Line" in the peer-reviewed journal PLOS ONE, Volume 12 issue 4. The publication follows extensive testing of the parent cells from which Protein Sciences' proprietary expresSF+® (SF+) cell line is derived. The study confirms that a contaminating rhabdovirus previously reported in a related cell line is not present in SF+ cells. These results demonstrate that not all cell lines are equal even if they are derived from the same parent cell line and highlight the high quality of the SF+ cell lineage.
Researchers at Johns Hopkins and George Washington universities report new evidence that proteins created by defective forms of HIV long previously believed to be harmless actually interact with our immune systems and are actively monitored by a specific type of immune cell, called cytotoxic T cells.
Scientists and researchers from all over the world who work on Bacillus anthracis, the causative agent of anthrax, and B. cereus and B. thuringiensis, two closely related bacillus species, will be heading to Victoria, British Columbia, in October for the international conference known as “Bacillus ACT.”
The 2014–2015 Ebola epidemic affected several countries in West Africa, leading to the death of more than 11'000 people. Although this epidemic of Ebolavirus disease is over, there is no knowing if, when or where another may strike. It is therefore more important than ever to find a reliable vaccine against this deadly disease. Research on vaccines, which was ongoing during the epidemic in West Africa, is now yielding promising results.
Many people might not have heard of the Aedes aegypti mosquito until this past year, when the mosquito, and the disease it can carry – Zika – began to make headlines. But more than 220 years ago, this same breed of mosquito was spreading a different and deadly epidemic right here in Philadelphia and just like Zika, this epidemic is seeing a modern resurgence, with Brazil at its epicenter.
Dr. Alessandro Sette’s team at La Jolla Institute for Allergy and Immunology has been named Best Academic Research Team as part of the 10th Vaccine Industry Excellence Awards at this year’s World Vaccine Congress 2017 held in Washington. The ViE Awards celebrate the outstanding contributions and achievements of leaders who continually set standards of excellence and advocacy in vaccine development.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right